Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
News|Videos|October 1, 2026

From Engagement to Enterprise Value: Reframing Community as a Growth Segment

Community engagement is a powerful tool but its impact depends on how it is done. When it begins early, is sustained over time, and is built through organizations and individuals communities already trust, it can expand access to historically overlooked and medically underserved populations worldwide. The result is more representative science, stronger participation across the drug-development lifecycle, and a sustainable pathway to commercial growth. Inside Edge’s proprietary global Trustmaker Network turns trusted community relationships into meaningful action helping people make informed health decisions while delivering measurable outcomes across R&D and commercial.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.